Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
JCO Oncology Practice|February 13, 2020
Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient CareVivek Kumar, Muhamad Alhaj-Moustafa, Leyla Bojanini, et al.
Advances in Radiation Oncology|August 19, 2021
Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueOmran Saifi, Scott C Lester, William Rule, et al.
British Journal of Haematology|January 29, 2024
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemiaRicardo D Parrondo, Navnita Dutta, Betsy R LaPlant, et al.
British Journal of Haematology|May 11, 2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patientsTaimur Sher, Sikander Ailawadhi, Kena C Miller, et al.
British Journal of Haematology|August 7, 2018
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cellsAneel Paulus, Alak Manna, Sharoon Akhtar, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
Blood Advances|December 24, 2025
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort StudyYoshito Nishimura, Thomas M Habermann, Morie A Gertz, et al.
Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.
Cancers|January 21, 2023
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple MyelomaSikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta, et al.
Blood|July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Pageof 12